Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O
InChI
InChIKey=QTBSBXVTEAMEQO-UHFFFAOYSA-N
InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
StereoComments | testing |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08eCurator's Comment: description was created based on several sources, including
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08e
Curator's Comment: description was created based on several sources, including
Acetic acid (a component of vinagre) is used in medicine for the treatment of otitis externa caused by bacterial infections. The solution containing acetic acid was approved by FDA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14668053https://www.ncbi.nlm.nih.gov/pubmed/2117062
Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: cyanide ions |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CYANOKIT Approved UseCyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3) Launch Date2006 |
|||
Curative | VOSOL Approved UseFor the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial. Launch Date1960 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4511.6 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, intramuscular Dose: 20 mg, 1 times / day Route: intramuscular Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 13 years |
|
20 g single, intravenous Highest studied dose Dose: 20 g Route: intravenous Route: single Dose: 20 g Sources: |
unhealthy, 26.9 years Health Status: unhealthy Age Group: 26.9 years Sex: M Sources: |
|
5 g single, intravenous Overdose |
unhealthy, 3 years |
|
5 g single, intravenous |
unhealthy, 62 years |
|
2000 ug 2 times / day multiple, oral Dose: 2000 ug, 2 times / day Route: oral Route: multiple Dose: 2000 ug, 2 times / day Sources: |
unhealthy, adult |
PubMed
Title | Date | PubMed |
---|---|---|
The utilization of acetate for synthesis in Escherichia coli. | 1954 Mar |
|
Microbiological degradation of diazepam. | 1975 |
|
Modification of drug action by hyperammonemia. | 1984 Apr |
|
Prevention of methionine and ammonia-induced coma by intravenous infusion of a branched chain amino acid solution to rats with liver injury. | 1984 Oct |
|
Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine. | 1985 |
|
Purification and characterization of aryl acylamidase from Nocardia globerula. | 1991 Jul 1 |
|
Location and sequence of the todF gene encoding 2-hydroxy-6-oxohepta-2,4-dienoate hydrolase in Pseudomonas putida F1. | 1991 Jul 31 |
|
Conversion of 4-hydroxyacetophenone into 4-phenyl acetate by a flavin adenine dinucleotide-containing Baeyer-Villiger-type monooxygenase. | 2000 Dec |
|
Brain dystrophin-glycoprotein complex: persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy. | 2001 |
|
Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. | 2001 Apr 6 |
|
Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. | 2001 Feb |
|
Exploring infection of wheat and carbohydrate metabolism in Mycosphaerella graminicola transformants with differentially regulated green fluorescent protein expression. | 2001 Feb |
|
In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during. | 2001 Feb |
|
Analgesic and anti-inflammatory effects of Mangifera indica L. extract (Vimang). | 2001 Feb |
|
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy. | 2001 Feb |
|
In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data. | 2001 Feb |
|
Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. | 2001 Feb |
|
Biodistribution of radiolabeled [(3)H] CMT-3 in rats. | 2001 Feb |
|
Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative beta1-selective adrenoceptor radioligand. | 2001 Feb |
|
Bacterial release of arsenic ions and organoarsenic compounds from soil contaminated by chemical warfare agents. | 2001 Feb |
|
DNA-protein crosslinks induced by nickel compounds in isolated rat lymphocytes: role of reactive oxygen species and specific amino acids. | 2001 Feb 1 |
|
Arginine catabolism by Thermanaerovibrio acidaminovorans. | 2001 Feb 20 |
|
A survey of lipolytic and glycolytic end-products in commercial Cheddar enzyme-modified cheese. | 2001 Jan |
|
Cation-exchange purification of mutagenized bovine beta-casein expressed in transgenic mouse milk: its putative Asn68-linked glycan is heterogeneous. | 2001 Jan |
|
In vitro mixed ruminal microorganism fermentation of whole cottonseed coated with gelatinized corn starch and urea. | 2001 Jan |
|
Teprenone promotes the healing of acetic acid-induced chronic gastric ulcers in rats by inhibiting neutrophil infiltration and lipid peroxidation in ulcerated gastric tissues. | 2001 Jan |
|
Physical stability of the blue pigments formed from geniposide of gardenia fruits: effects of pH, temperature, and light. | 2001 Jan |
|
N(delta)-(5-hydroxy-4,6-dimethylpyrimidine-2-yl)-l-ornithine, a novel methylglyoxal-arginine modification in beer. | 2001 Jan |
|
Structure and dynamics of high molecular weight glutenin subunits of durum wheat (Triticum durum) in water and alcohol solutions studied by electron paramagnetic resonance and circular dichroism spectroscopies. | 2001 Jan |
|
Peripheral and preemptive opioid antinociception in a mouse visceral pain model. | 2001 Jan |
|
Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate. | 2001 Jan |
|
Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. | 2001 Jan |
|
Decolorization of azo-reactive dye by polyphosphate- and glycogen-accumulating organisms in an anaerobic-aerobic sequencing batch reactor. | 2001 Jan |
|
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores. | 2001 Jan 22 |
|
Identification of lactic acid bacteria constituting the predominating microflora in an acid-fermented condiment (tempoyak) popular in Malaysia. | 2001 Jan 22 |
|
Di-tert-butyl phosphate complexes of cobalt(II) and zinc(II) as precursors for ceramic M(PO3)2 and M2P2O7 materials: synthesis, spectral characterization, structural studies, and role of auxiliary ligands. | 2001 Jan 29 |
|
[DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers. | 2001 Jan 5 |
|
Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis. | 2001 Jan 5 |
|
Metabolic fate of [14C]-ethanol into endothelial cell phospholipids including platelet-activating factor, sphingomyelin and phosphatidylethanol. | 2001 Jan-Feb |
|
S-methyl-N,N-diethylthiocarbamate sulfoxide elicits neuroprotective effect against N-methyl-D-aspartate receptor-mediated neurotoxicity. | 2001 Jan-Feb |
|
Salt accumulation resulting from base added for pH control, and not ethanol, limits growth of Thermoanaerobacteriumthermosaccharolyticum HG-8 at elevated feed xylose concentrations in continuous culture. | 2001 Jan-Feb |
|
Conversion of sugars to 1,2-propanediol by Thermoanaerobacterium thermosaccharolyticum HG-8. | 2001 Jan-Feb |
|
Acute and chronic toxicity of Potassium Chloride (KCl) and Potassium Acetate (KC(2)H(3)O(2)) to Daphnia similis and Ceriodaphnia dubia (Crustacea; Cladocera). | 2001 Mar |
|
Measurement of low picomolar levels of triamcinolone acetonide in human bronchoalveolar lavage fluid by gas chromatography-electron-capture negative-ion mass spectrometry. | 2001 Mar 1 |
|
Utilization of geraniol is dependent on molybdenum in Pseudomonas aeruginosa: evidence for different metabolic routes for oxidation of geraniol and citronellol. | 2005 Jul |
|
Effects of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, arginase and related metabolites in different regions of rat brain. | 2005 Oct |
|
Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates. | 2009 Apr 1 |
|
AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis. | 2010 Jan 22 |
|
Effects of ammonia and allopurinol on rat hippocampal NMDA receptors. | 2010 Mar |
|
Direct exposure to ammonia and hyperammonemia increase the extracellular accumulation and degradation of astroglia-derived glutathione in the rat prefrontal cortex. | 2010 Sep |
Patents
Sample Use Guides
Cyanokit (hydroxocobalamin for injection): one 5 g vial is a complete starting dose
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6692038
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:47:13 GMT 2025
by
admin
on
Mon Mar 31 17:47:13 GMT 2025
|
Record UNII |
Q40Q9N063P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 447
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1025
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1081
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 323
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1247
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 724
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
28
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ATC |
S02AA10
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
JECFA EVALUATION |
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 879
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
NCI_THESAURUS |
C254
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
FDA ORPHAN DRUG |
706219
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ATC |
G01AD02
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-VATC |
QG01AD02
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1144
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
DSLD |
396 (Number of products:5)
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1096
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 951
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1236
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
CFR |
21 CFR 184.1005
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 908
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 728
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 993
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-260
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1035
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 887
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1132
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-VATC |
QS02AA10
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1089
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 880
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 561
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 140
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
JECFA EVALUATION |
INS-260
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1082
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 801
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1094
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
15366
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
Acetic acid (medical use)
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
406306
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
168
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID5024394
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
200-580-7
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
1005706
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
100000088999
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
4211
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | Description: Clear, colourless liquids. At a temperature below 15 ?C Glacial acetic acid may occur as a translucent, crystalline mass; odour, characteristic and pungent. Miscibility: Miscible with water, ethanol (~750 g/l) TS, and glycerol R. Category: Acidifying agent. Storage: Acetic acid should be kept in a tightly closed container. Additional information: Glacial acetic acid is flammable and should be handled with care. Congealing point, about 15 ?C. | ||
|
D019342
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
SUB11689MIG
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
CHEMBL539
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
3
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
176
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
127175
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
64-19-7
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
C61623
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
112209
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
m1324
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | Merck Index | ||
|
39
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
132953
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
463-83-2
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
ALTERNATIVE | |||
|
Q40Q9N063P
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
DB03166
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
115870
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
SUB12711MIG
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
Q40Q9N063P
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
111201
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (GC)
USP
|
||
|
PARENT -> IMPURITY |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|